Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 8/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1696048 | 0.86 | MAPT (0.49) | MAPTMAOBCMA1HDAC3HDAC4 | |
| SCHEMBL12074605 | 0.86 | MAPT (0.49) | MAPTMAOBCMA1HDAC3HDAC4 | |
| SCHEMBL3990717 | 0.81 | TACR1 (0.45) | MAPTCMA1ALOX5RAB9ANPC1 | |
| SCHEMBL16476709 | 0.80 | CASP3 (0.43) | MAPTMAOBCMA1ALOX5RAB9A | |
| SCHEMBL1696189 | 0.80 | CASP3 (0.43) | MAPTMAOBCMA1ALOX5RAB9A | |
| SCHEMBL4855970 | 0.79 | ACLY (0.39) | MAPTMAOBNPSR1HDAC1HDAC8 | |
| SCHEMBL16476721 | 0.78 | KMT2A (0.46) | MAPTCMA1ALOX5RAB9ANPC1 | |
| SCHEMBL1696332 | 0.77 | POLB (0.47) | CMA1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL12073587 | 0.77 | POLB (0.47) | CMA1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL7576844 | 0.74 | ALDH1A1 (0.56) | MAPTNPSR1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754754-B2 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2010-07-13 | — | — | US | claimed |
| EP-1596852-B1 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-05-27 | — | — | EP | claimed |
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2006-02-02 | — | — | US | claimed |
| EP-1596852-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| WO-2004071380-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2004-08-26 | — | — | WO | claimed |
| US-7754754-B2 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| EP-1596852-B1 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | GRUENENTHAL GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| EP-1596852-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004071380-A2 | DRUGS CONTAINING SUBSTITUTED 2-ARYL-AMINOACETIC ACID COMPOUNDS | Grünenthal GmbH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025473-A1 | Pharmaceutical formulations containing substituted 2 heteroarylaminoacetic acid compounds | AADAT, DDC, AADAC | MAPT 1322/4885MAOB 179/4885CMA1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.